APVO414 / Aptevo Therap - LARVOL DELTA

".@BirkhoelzerS .@BritishCardioSo .@TheBHF .@RDMOxford .@cardiacsmart .@NWambulance .@DrSarahClarke .@CaraCarahendry .@ShrillaB .@aayshacader .@ACCWIC_CT .@MinnowWalsh .@ditchhaporia .@drmalissawood .@AndresZ41407831 .@simonmgillespie .@AnastasiaSMihai .@NSLHD .@KollingINST" (@rcpEspana)

Hybrid Proteins with Short Conformational Epitopes of the Receptor-Binding Domain of SARS-CoV-2 Spike Protein Promote Production of Virus-Neutralizing Antibodies When Used for Immunization. (PubMed, Biochemistry (Mosc)) - "The most pronounced increase in the cytokine synthesis was observed in response to the proteins containing epitopes with disulfide bonds (452-494, 470-491), as well as epitopes 414-425 and 496-507. For some recombinant proteins with short conformational epitopes, adjuvant optimization allowed to obtained mouse sera displaying virus-neutralizing activity in the microneutralization assay with live SARS-CoV-2 (hCoV-19/Russia/StPetersburg-3524/2020 EPI_ISL_415710 GISAID). The results obtained can be used to develop epitope vaccines for prevention of COVID-19 and other viral infections."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Association of High Screen-Time Use With School-age Cognitive, Executive Function, and Behavior Outcomes in Extremely Preterm Children. (PubMed, JAMA Pediatr) - "This cohort study was a secondary analysis from the Eunice Kennedy Shriver National Institute of Child Health and Human Development Surfactant Positive Airway Pressure and Pulse Oximetry Randomized Trial Neuroimaging and Neurodevelopmental Outcomes school-aged cohort and includes 414 EPT children born between February 1, 2005, and February 28, 2009, and evaluated in between 2012 and 2016 at ages 6 years 4 months to 7 years 2 months...The findings of this study suggest that high screen time contributes to adverse cognitive, executive function, and behavior outcomes at ages 6 to 7 years in children born at less than 28 weeks. These findings support the need for clinicians to have heightened awareness of the risks for EPT children and discuss both the benefits and risks of screen time with families."

Clinical • Journal

Improving the Expression of Human Granulocyte Colony Stimulating Factor in Escherichia coli by Reducing the GC-content and Increasing mRNA Folding Free Energy at 5'-Terminal End. (PubMed, Adv Pharm Bull) - "Those DNA fragments were individually cloned into pJexpress414 expression vector and were confirmed using restriction and DNA sequencing analyses...This study emphasized the important role of the nucleotide composition immediately downstream the start codon to achieve high-yield protein product on heterologous expression in E. coli."

Journal

Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1; N=130; Not yet recruiting; Sponsor: Emergent Product Development Seattle LLC

New P1 trial • Biosimilar • Oncology • Prostate Cancer

Physical Activity and Sedentary Patterns among Metabolically Healthy Individuals Living with Obesity. (PubMed, J Diabetes Res) - "...This study includes 414 youth (12-18 years old), 802 adults (19-44 years old), and 1230 older adults (45-85 years old) living with obesity from the 2003-2004 or 2005-2006 NHANES cycles...When adjusted for confounders, all bouts of sedentary behavior patterns in youth were significantly associated with being classified as MHO. This study suggests that greater sedentary time is associated with cardiometabolic risk factors in youth even if they are physically active."

Clinical • Journal • Biosimilar • Metabolic Disorders • Obesity

MOR209/ES414, A Novel Bispecific Antibody Targeting PSMA For The Treatment of Metastatic Castration-Resistant Prostate Cancer. (PubMed) - "Administration of MOR209/ES414 in murine xenograft models of human prostate cancer significantly inhibited tumor growth, prolonged survival and decreased serum prostate-specific antigen levels only in the presence of adoptively transferred human T cells. Based on these preclinical findings, MOR209/ES414 warrants further investigation as a potential therapeutic for the treatment of CRPC."

Journal • Biosimilar • Gene Therapies • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer

APVO414: Preliminary top-line data from P1 trial (NCT02262910) in mCRPC at the end of 2018 (Aptevo Therapeutics) - Q1 2018 Results

P1 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer

Study of ES414 in Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1; N=130; Active, not recruiting; Sponsor: Aptevo Therapeutics; Recruiting ➔ Active, not recruiting

Enrollment closed • Biosimilar • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer

APVO414: Completion of enrollment in P1 trial (NCT02262910) for mCRPC in Q3 2018 (Aptevo Therapeutics) - Investor Presentation

Enrollment status • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer

MorphoSys: Company Update (Morphosys) - Anticipated initiation of P1/2 dose extension trial (N=80) in mCRPC in 2016

Anticipated trial initiation date • Oncology • Prostate Cancer

MorphoSys: Consolidated Financial Statements (IFRS) 2015 (Morphosys) - Anticipated expiry of patents in 2032

Anticipated patent expiry • Oncology

During day and night: Childhood psychotic experiences and objective and subjective sleep problems. (PubMed, Schizophr Res) - "Childhood psychotic experiences were not associated with objective sleep measures. In contrast, psychotic experiences were associated with nightmares, which are a known risk indicator of psychopathology in pre-adolescence. More research is needed to shed light on the potential etiologic or diagnostic role of nightmares in the development of psychotic phenomena."

Clinical • Journal

Study of ES414 in Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1; N=35; Completed; Sponsor: Aptevo Therapeutics; Active, not recruiting ➔ Completed; N=130 ➔ 35; Trial completion date: Dec 2020 ➔ Feb 2019; Trial primary completion date: Dec 2019 ➔ Dec 2018

Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date

Correlation between GH and IGF-1 during treatment for acromegaly. (PubMed, J Neurosurg) - "Nonlinearity between GH and IGF-1 occurs at GH levels far below those previously recognized. To monitor tumor activity and tumor viability requires measurement of GH levels."

Journal

Construction and Characterization of a Medium Copy Number Expression Vector Carrying Auto-Inducible dps Promoter to Overproduce a Bacterial Superoxide Dismutase in Escherichia coli. (PubMed, Mol Biotechnol) - "pCADsod displayed the highest stability compared with pBMsod and pJEXpress414sod by plasmid retention assay. We demonstrate the use of an auto-inducible dps promoter to express high level of heterologous protein, an SOD of S. equorum, from a stable expression vector with medium copy number."

Journal

Aptevo Therapeutics reports third quarter 2018 financial results (GlobeNewswire) - "Commenced site activation for the APVO436 Phase 1/1b open-label clinical study; anticipate patient dosing to commence shortly.......we have made the decision to focus our resources on our next-generation candidates, which we consider to be the most promising opportunities in our pipeline, and discontinue further development of our first-generation ADAPTIR candidates, otlertuzumab and APVO414. Going forward we will close the otlertuzumab and APVO414 clinical studies to further enrollment but will continue to monitor patients remaining on therapy."

Enrollment status • Trial status